Subtitle
Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy.
Subtitle
Treatment of primary or recurrent non-resectable pancreatic cancer with proton beam irradiation combined with gemcitabine-based chemotherapy.
Proto therapy Time
July and August 2023
Executive summary
This study reported results of 25 patients with localized nonresectable pancreatic cancer (15 patients) or local recurrent disease (10 patients) treated with chemoradiation using PBT. The median progression-free survival was 5.9 months and median overall survival was 11.0 months. Four grade 3 and 4 acute adverse events were reported.
Other popular content
Proton Therapy Publication
December 2021
Technical insights on the treatment of GI cancers.
Proton Therapy Publication
October 2021
Impact of lymphopenia on the clinical outcomes of esophageal cancer patients
Proton Therapy Publication
October 2021
Acute Hematological Outcomes after Proton and Photon Beam Craniospinal Irradiation in Pediatric Brain Tumors
Proton Therapy Publication
October 2021
Acute Hematological Outcomes in Pediatric Brain Tumors
Proton Therapy Publication
October 2021
Comparison of hypothyroidism and adrenal insufficiency in children with medulloblastoma
Proton Therapy Publication
September 2021
Scoping review of patient selection methods for proton therapy
Proton Therapy Publication
September 2021
Dosimetry, efficacy, safety, and cost-effectiveness of PT for NSCLC
Proton Therapy Publication
September 2021
Reduced diffusion in white matter after radiotherapy with photons and protons
Proton Therapy Publication
September 2021
Particle Radiotherapy for Skull Base Chondrosarcoma
Proton Therapy Publication
September 2021
Assessing concordance between patient-reported and investigator-reported CTCAE after PBT for prostate cancer.
Proton Therapy Publication
September 2021
Current status and application of proton therapy for esophageal cancer
Proton Therapy Publication
September 2021
Bicentric Treatment Outcomes following PT for Non-Myxopapillary High-Grade Spinal Cord Ependymoma in Children
Proton Therapy Publication
September 2021
Identifying individualized risk profiles for radiotherapy-induced lymphopenia
Proton Therapy Publication
September 2021
FLASH proton radiotherapy spares normal epithelial and mesenchymal tissues while preserving sarcoma response
Proton Therapy Publication
August 2021
Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma